Sudhir Agrawal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9228435/publications.pdf

Version: 2024-02-01

181 papers	9,216 citations	28190 55 h-index	53109 85 g-index
184 all docs	184 docs citations	184 times ranked	6252 citing authors

#	Article	IF	Citations
1	Introduction and History of the Chemistry of Nucleic Acids Therapeutics. Methods in Molecular Biology, 2022, 2434, 3-31.	0.4	5
2	Tilsotolimod with Ipilimumab Drives Tumor Responses in Antiâ€“PD-1 Refractory Melanoma. Cancer Discovery, 2021, 11, 1996-2013.	7.7	32
3	The Evolution of Antisense Oligonucleotide Chemistryâ€”A Personal Journey. Biomedicines, 2021, 9, 503.	1.4	13
4	Suppression of Kv3.3 channels by antisense oligonucleotides reverses biochemical effects and motor impairment in spinocerebellar ataxia type 13 mice. FASEB Journal, 2021, 35, e22053.	0.2	5
5	RNA Therapeutics Are Stepping Out of the Maze. Trends in Molecular Medicine, 2020, 26, 1061-1064.	3.5	7
6	Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors. Immuno-Oncology Technology, 2019, 3, 15-23.	0.2	14
7	Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy. International Journal of Oncology, 2018, 53, 1193-1203.	1.4	41
8	Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis. Atherosclerosis, 2017, 261, 26-36.	0.4	37
9	Inhibition of Mef2a Enhances Neovascularization via Post-transcriptional Regulation of 14q32 MicroRNAs miR-329 and miR-494. Molecular Therapy - Nucleic Acids, 2017, 7, 61-70.	2.3	18
10	RAGE Enhances TLR Responses through Binding and Internalization of RNA. Journal of Immunology, 2016, 197, 4118-4126.	0.4	51
11	Sa1757 Targeting Innate Immune Receptors to Treat Inflammatory Bowel Disease: Preclinical Activity of IMO-9200, an Antagonist of TLRS 7, 8, and 9 in Mouse Models of Colitis. Gastroenterology, 2015, 148, S-324.	0.6	5
12	Role of toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. Human Molecular Genetics, 2014, 23, 2604-2617.	1.4	54
13	Cutting Edge: The UNC93B1 Tyrosine-Based Motif Regulates Trafficking and TLR Responses via Separate Mechanisms. Journal of Immunology, 2014, 193, 3257-3261.	0.4	37
14	Design of synthetic oligoribonucleotide-based agonists of Toll-like receptor 3 and their immune response profiles in vitro and in vivo. Organic and Biomolecular Chemistry, 2013, 11, 1049.	1.5	7
15	A Toll-Like Receptor 7, 8, and 9 Antagonist Inhibits Th1 and Th17 Responses and Inflammasome Activation in a Model of IL-23-Induced Psoriasis. Journal of Investigative Dermatology, 2013, 133, 1777-1784.	0.3	66
16	Immune-Stimulatory Dinucleotide at the 5â€²-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses. ACS Medicinal Chemistry Letters, 2013, 4, 302-305.	1.3	8
17	Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Research, 2013, 41, 3947-3961.	6.5	62
18	A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice. Autoimmunity, 2013, 46, 419-428.	1.2	54

#	Article	IF	Citations
19	TLR9 Agonist Protects Mice from Radiation-Induced Gastrointestinal Syndrome. PLoS ONE, 2012, 7, e29357.	1.1	65
20	An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy. PLoS ONE, 2012, 7, e38111.	1.1	51
21	Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers. Clinical Cancer Research, 2011, 17, 6531-6541.	3.2	47
22	Modulation of Endosomal Toll-Like Receptor-Mediated Immune Responses by Synthetic Oligonucleotides. Advances in Polymer Science, 2011, , 61-93.	0.4	8
23	Novel Oligonucleotides Containing Two 3â€²-Ends Complementary to Target mRNA Show Optimal Gene-Silencing Activity. Journal of Medicinal Chemistry, 2011, 54, 3027-3036.	2.9	18
24	Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists. Cellular Immunology, 2011, 270, 126-134.	1.4	14
25	PKA knockdown enhances cell killing in response to radiation and androgen deprivation. International Journal of Cancer, 2011, 128, 962-973.	2.3	19
26	Synthesis and immunological activities of novel agonists of toll-like receptor 9. Cellular Immunology, 2010, 263, 105-113.	1.4	14
27	Antitumor Activity and Immune Response Induction of a Dual Agonist of Toll-Like Receptors 7 and 8. Molecular Cancer Therapeutics, 2010, 9, 1788-1797.	1.9	35
28	Peptide Conjugation at the 5â€²-End of Oligodeoxynucleotides Abrogates Toll-Like Receptor 9-Mediated Immune Stimulatory Activity. Bioconjugate Chemistry, 2010, 21, 39-45.	1.8	38
29	A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine. Vaccine, 2010, 28, 3522-3530.	1.7	18
30	Coadministration of Telomerase Genetic Vaccine and a Novel TLR9 Agonist in Nonhuman Primates. Molecular Therapy, 2009, 17, 1804-1813.	3.7	22
31	Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9. Clinical Cancer Research, 2009, 15, 1575-1584.	3.2	44
32	A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action. Clinical Cancer Research, 2009, 15, 6921-6930.	3.2	35
33	Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2044-2047.	1.0	16
34	Toll-like Receptor 7 Selective Synthetic Oligoribonucleotide Agonists: Synthesis and Structureâ^'Activity Relationship Studies. Journal of Medicinal Chemistry, 2009, 52, 6871-6879.	2.9	26
35	Modifications Incorporated in CpG Motifs of Oligodeoxynucleotides Lead to Antagonist Activity of Toll-like Receptors 7 and 9. Journal of Medicinal Chemistry, 2009, 52, 5108-5114.	2.9	56
36	Oligodeoxyribonucleotide-Based Antagonists for Toll-Like Receptors 7 and 9. Journal of Medicinal Chemistry, 2009, 52, 551-558.	2.9	41

#	Article	IF	Citations
37	Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8. Biochemical and Biophysical Research Communications, 2009, 386, 443-448.	1.0	31
38	Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. Journal of Neurochemistry, 2008, 79, 426-436.	2.1	100
39	Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo. Prostate, 2008, 68, 599-609.	1.2	23
40	Impact of Secondary Structure of Toll-Like Receptor 9 Agonists on Interferon Alpha Induction. Antimicrobial Agents and Chemotherapy, 2008, 52, 4320-4325.	1.4	26
41	Antisense MDM2 Enhances E2F1-Induced Apoptosis and the Combination Sensitizes Androgen-Dependent and Androgen-Independent Prostate Cancer Cells to Radiation. Molecular Cancer Research, 2008, 6, 1742-1754.	1.5	12
42	TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12468-12473.	3.3	63
43	Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13750-13755.	3.3	69
44	Immune Modulatory Oligonucleotides in the Prevention and Treatment of OVAâ€Induced Eustachian Tube Dysfunction in Rats. Otolaryngology - Head and Neck Surgery, 2007, 137, 321-326.	1.1	8
45	Immune Modulatory Oligonucleotides in Prevention of Nasal Allergenâ€"Induced Eustachian Tube Dysfunction in Rats. Otolaryngology - Head and Neck Surgery, 2007, 137, 250-255.	1.1	11
46	Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice. Journal of Allergy and Clinical Immunology, 2007, 120, 631-637.	1.5	58
47	Agonists of Toll-like Receptor 9 Containing Synthetic Dinucleotide Motifs. Journal of Medicinal Chemistry, 2007, 50, 6411-6418.	2.9	23
48	Antisense-MDM2 Sensitizes LNCaP Prostate Cancer Cells to Androgen Deprivation, Radiation, and the Combination In Vivo. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1151-1160.	0.4	28
49	The role of immunomodulatory oligonucleotides in prevention of OVA-induced Eustachian tube dysfunction. International Journal of Pediatric Otorhinolaryngology, 2006, 70, 2019-2026.	0.4	8
50	Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice. Vaccine, 2006, 24, 1470-1477.	1.7	6
51	Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications. Nucleic Acids Research, 2006, 34, 3231-3238.	6.5	16
52	Chemotherapy and chemosensitization of nonâ€"small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Molecular Cancer Therapeutics, 2006, 5, 1585-1592.	1.9	56
53	Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors. Clinical Cancer Research, 2006, 12, 577-583.	3.2	86
54	Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Molecular Cancer Therapeutics, 2006, 5, 2106-2114.	1.9	36

#	Article	IF	Citations
55	Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis. Clinical Cancer Research, 2006, 12, 5231-5241.	3.2	136
56	Novel MDM2 p53-Independent Functions Identified through RNA Silencing Technologies. Annals of the New York Academy of Sciences, 2005, 1058, 205-214.	1.8	22
57	Application of XIAP Antisense to Cancer and Other Proliferative Disorders: Development of AEG35156/GEM(R)640. Annals of the New York Academy of Sciences, 2005, 1058, 215-234.	1.8	56
58	Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene, 2005, 24, 7238-7247.	2.6	111
59	Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6925-6930.	3.3	95
60	Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotides: Proof of Principle, In Vitro and In Vivo Activities, and Mechanisms. Current Cancer Drug Targets, 2005, 5, 43-49.	0.8	53
61	Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice. International Immunopharmacology, 2005, 5, 981-991.	1.7	19
62	Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity. Vaccine, 2005, 23, 2614-2622.	1.7	30
63	Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models. Clinical Cancer Research, 2004, 10, 1263-1273.	3.2	60
64	Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. International Journal of Oncology, 2004, 24, 901.	1.4	12
65	Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer. Clinical Cancer Research, 2004, 10, 4858-4864.	3.2	48
66	MDM2 Is a Negative Regulator of p21 , Independent of p53. Journal of Biological Chemistry, 2004, 279, 16000-16006.	1.6	223
67	Antisense and siRNA as agonists of Toll-like receptors. Nature Biotechnology, 2004, 22, 1533-1537.	9.4	119
68	Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene, 2004, 23, 8105-8117.	2.6	165
69	Impact of Site-Specific Nucleobase Deletions on the Arthritogenicity of DNA. Inflammation, 2004, 28, 159-168.	1.7	1
70	Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. Prostate, 2004, 60, 187-196.	1.2	20
71	Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. International Journal of Radiation Oncology Biology Physics, 2004, 58, 336-343.	0.4	32
72	Hybridization-based fluorescence assay allows quantitation of single-stranded oligodeoxynucleotides in low nanomolar range. Analytical Biochemistry, 2004, 328, 93-95.	1.1	3

#	Article	IF	Citations
73	Induction of immune activation by a novel immunomodulatory oligonucleotide without thymocyte apoptosis. Biochemical and Biophysical Research Communications, 2004, 318, 60-66.	1.0	8
74	Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. International Immunopharmacology, 2004, 4, 127-138.	1.7	33
75	Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice. International Immunopharmacology, 2004, 4, 851-862.	1.7	16
76	Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA. Annals of the New York Academy of Sciences, 2003, 1002, 30-42.	1.8	42
77	Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti-MDM2 Oligonucleotides. Annals of the New York Academy of Sciences, 2003, 1002, 217-235.	1.8	54
78	Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms. Prostate, 2003, 54, 194-205.	1.2	86
79	Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA. Bioorganic and Medicinal Chemistry, 2003, 11, 459-464.	1.4	38
80	Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells. Biochemical and Biophysical Research Communications, 2003, 310, 1133-1139.	1.0	29
81	CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochemical and Biophysical Research Communications, 2003, 300, 853-861.	1.0	30
82	Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Biochemical and Biophysical Research Communications, 2003, 306, 948-953.	1.0	39
83	Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Research, 2003, 31, 2393-2400.	6.5	62
84	Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11636-11641.	3.3	179
85	A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14303-14308.	3.3	58
86	Was Induction of HIV-1 Through TLR9?. Journal of Immunology, 2003, 171, 1621-1622.	0.4	25
87	Chemistry of CpG DNA. Current Protocols in Nucleic Acid Chemistry, 2003, 12, Unit 4.16.	0.5	0
88	'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Research, 2002, 30, 4460-4469.	6.5	70
89	Immunostimulatory properties of phosphorothioate CpG DNA containing both 3'-5'- and 2'-5'-internucleotide linkages. Nucleic Acids Research, 2002, 30, 1613-1619.	6.5	32
90	Conjugation of Ligands at the 5â€˜-End of CpG DNA Affects Immunostimulatory Activity. Bioconjugate Chemistry, 2002, 13, 966-974.	1.8	84

#	Article	IF	Citations
91	Design, Synthesis, and Immunostimulatory Properties of CpG DNAs Containing Alkyl-Linker Substitutions:Â Role of Nucleosides in the Flanking Sequences. Journal of Medicinal Chemistry, 2002, 45, 4540-4548.	2.9	37
92	Thermal stressâ€“induced HSP70 mediates protection against intrapancreatic trypsinogen activation and acute pancreatitis in rats. Gastroenterology, 2002, 122, 156-165.	0.6	87
93	Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochemical and Biophysical Research Communications, 2002, 297, 83-90.	1.0	47
94	Medicinal chemistry and therapeutic potential of CpG DNA. Trends in Molecular Medicine, 2002, 8, 114-121.	3.5	76
95	Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent Mechanisms. Molecular Medicine, 2002, 8, 185-199.	1.9	48
96	Modulation of immunostimulatory activity of CpG oligonucleotides by site-Specific deletion of nucleobases. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2263-2267.	1.0	44
97	Effect of chemical modifications of cytosine and guanine in a cpg-motif of oligonucleotides: structureâ€“immunostimulatory activity relationships. Bioorganic and Medicinal Chemistry, 2001, 9, 807-813.	1.4	71
98	Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. International Journal of Cancer, 2001, 93, 172-178.	2.3	87
99	Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorganic and Medicinal Chemistry, 2001, 9, 2803-2808.	1.4	45
100	Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides. International Journal of Oncology, 2001, 18, 1061-9.	1.4	4
101	The Cockayne syndrome group B DNA repair protein as an anti-cancer target. International Journal of Oncology, 2001, 19, 1089-97.	1.4	6
102	Stabilization of the MDM2 Oncoprotein by Mutant p53. Journal of Biological Chemistry, 2001, 276, 6874-6878.	1.6	60
103	Antisense and/or Immunostimulatory Oligonucleotide Therapeutics. Current Cancer Drug Targets, 2001, 1, 197-209.	0.8	83
104	A novelMDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. International Journal of Cancer, 2000, 88, 804-809.	2.3	68
105	Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1051-1054.	1.0	48
106	Accessible 5â€²-end of CpG-containing Phosphorothioate Oligodeoxynucleotides is essential for immunostimulatory activity. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2585-2588.	1.0	78
107	â€˜Cycliconsâ€™ as hybridization-based fluorescent primer-probes: synthesis, properties and application in real-time PCR. Bioorganic and Medicinal Chemistry, 2000, 8, 1911-1916.	1.4	24
108	Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties. Bioorganic and Medicinal Chemistry, 2000, 8, 275-284.	1.4	77

#	Article	IF	Citations
109	Antisense therapeutics: is it as simple as complementary base recognition?. Trends in Molecular Medicine, 2000, 6, 72-81.	2.6	125
110	Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus. Antiviral Research, 2000, 48, 187-196.	1.9	27
111	Biodistribution and Metabolism of a Mixed Backbone Oligonucleotide (GEM 231) Following Single and Multiple Dose Administration in Mice. Oligonucleotides, 2000, 10, 333-345.	4.4	19
112	Intratumoral Pharmacokinetics of Oligonucleotides in a Tissue-Isolated Tumor Perfusion System. Oligonucleotides, 2000, 10, 105-110.	4.4	7
113	The Roles of E6-AP and MDM2 in p53 Regulation in Human Papillomavirus-Positive Cervical Cancer Cells. Oligonucleotides, 2000, 10, 17-27.	4.4	26
114	Heat shock protein 70 prevents secretagogue-induced cell injury in the pancreas by preventing intracellular trypsinogen activation. Journal of Clinical Investigation, 2000, 106, 81-89.	3.9	76
115	Ubiquitous Induction of p53 in Tumor Cells by Antisense Inhibition of MDM2 Expression. Molecular Medicine, 1999, 5, 21-34.	1.9	78
116	Dual Blockade of Cyclic AMP Response Element- (CRE) and AP-1-directed Transcription by CRE-transcription Factor Decoy Oligonucleotide. Journal of Biological Chemistry, 1999, 274, 1573-1580.	1.6	113
117	Site of chemical modifications in CpG containing phosphorothiate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3453-3458.	1.0	56
118	Pseudo-cyclic oligonucleotides: in vitro and in vivo properties. Bioorganic and Medicinal Chemistry, 1999, 7, 2727-2735.	1.4	4
119	Cell binding, uptake and cytosolic partition of HIV anti-gag Phosphodiester oligonucleotides 3â€²-linked to cholesterol derivatives in macrophages. Bioorganic and Medicinal Chemistry, 1999, 7, 2263-2269.	1.4	18
120	Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RI alpha subunit: p53-independent mechanism of action. Molecular and Cellular Biochemistry, 1999, 195, 25-36.	1.4	31
121	Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1999, 1489, 53-67.	2.4	160
122	EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. , 1999, 80, 589-594.		39
123	Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscular Disorders, 1999, 9, 330-338.	0.3	190
124	Mixed-Backbone Oligonucleotides Containing Segments of Deoxynucleosides Phosphorothioate and 2'-O-Methylribonucleosides Methylphosphonate: Synthesis and Properties. Phosphorus, Sulfur and Silicon and the Related Elements, 1999, 144, 363-366.	0.8	1
125	Antisense depletion of RIÎ± subunit of protein kinase A induces apoptosis and growth arrest in human breast cancer cells. Breast Cancer Research and Treatment, 1998, 49, 97-107.	1.1	28
126	Impact of mixed-backbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by Escherichia coli RNase H. Bioorganic and Medicinal Chemistry, 1998, 6, 1695-1705.	1.4	28

#	Article	IF	Citations
127	Synergistic inhibition of HIV-1 by an antisense oligonucleotide and nucleoside analog reverse transcriptase inhibitors. Antiviral Research, 1998, 38, 63-73.	1.9	9
128	Solid-phase stereoselective synthesis of oligonucleoside phosphorothioates: The nucleoside bicyclic oxazaphospholidines as novel synthons. Tetrahedron Letters, 1998, 39, 2491-2494.	0.7	52
129	Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotides on human complement and coagulation. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2103-2108.	1.0	14
130	Solid-phase stereoselective synthesis of 2â€²-O-methyl-oligoribonucleoside phosphorothioates using nucleoside bicyclic oxazaphospholidines. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2539-2544.	1.0	19
131	Mixed-Backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 3269-3274.	1.0	39
132	Antisense therapeutics. Current Opinion in Chemical Biology, 1998, 2, 519-528.	2.8	212
133	Cellular Distribution of Phosphorothioate Oligonucleotide Following Intravenous Administration in Mice. Oligonucleotides, 1998, 8, 451-458.	4.4	37
134	A Mild and Efficient Solid-Support Synthesis of Novel Oligonucleotide Conjugates. Bioconjugate Chemistry, 1998, 9, 283-291.	1.8	14
135	Cooperative Inhibition of Renal Cancer Growth by Anti-Epidermal Growth Factor Receptor Antibody and Protein Kinase A Antisense Oligonucleotide. Journal of the National Cancer Institute, 1998, 90, 1087-1998.	3.0	72
136	Cooperative Antitumor Effect of Mixed Backbone Oligonucleotides Targeting Protein Kinase A in Combination with Cytotoxic Drugs or Biologic Agents. Oligonucleotides, 1998, 8, 141-145.	4.4	11
137	Effect of Aspirin on Protein Binding and Tissue Disposition of Oligonucleotide Phosphorothioate in Rats. Journal of Drug Targeting, 1998, 5, 303-312.	2.1	26
138	Pharmacokinetics and Metabolism of an Oligodeoxynucleotide Phosphorothioate (GEM91Â®) in Cynomolgus Monkeys Following Intravenous Infusion. Oligonucleotides, 1998, 8, 43-52.	4.4	33
139	Mixed Backbone Oligonucleotides: Improvement in Oligonucleotide-induced Toxicity In Vivo. Oligonucleotides, 1998, 8, 135-139.	4.4	75
140	Repression of Human Thymidylate Synthase mRNA Translation by Antisense 2â€²-O-Methyl Oligoribonucleotides. Oligonucleotides, 1998, 8, 371-378.	4.4	5
141	In VivoPharmacokinetics of Phosphorothioate Oligonucleotides Containing Contiguous Guanosines. Oligonucleotides, 1997, 7, 245-249.	4.4	28
142	Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Oligonucleotides in Mice. Oligonucleotides, 1997, 7, 495-502.	4.4	93
143	Mixed-Backbone Oligonucleotides Containing Phosphorothioate and Methylphosphonate Linkages as Second Generation Antisense Oligonucleotide. Nucleosides & Nucleotides, 1997, 16, 927-936.	0.5	9
144	Single-Stranded DNA and RNA Targeted Triplex-Formation: UV, CD and Molecular Modeling Studies of Foldback Triplexes Containing Different RNA, 2â€²-OMe-RNA and DNA Strand Combinations. Journal of Biomolecular Structure and Dynamics, 1997, 14, 715-726.	2.0	10

#	Article	IF	Citations
145	Toxicologic Effects of an Oligodeoxynucleotide Phosphorothioate and Its Analogs Following Intravenous Administration in Rats. Oligonucleotides, 1997, 7, 575-584.	4.4	39
146	Synthesis, Biophysical Properties, and Stability Studies of Mixed Backbone Oligonucleotides Containing Novel Non-Ionic Linkages. Nucleosides & Nucleotides, 1997, 16, 1491-1495.	0.5	2
147	In VivoMetabolic Profile of a Phosphorothioate Oligodeoxyribonucleotide. Oligonucleotides, 1997, 7, 159-165.	4.4	47
148	Restoration of ÃŸ-Globin Gene Expression in Mammalian Cells by Antisense Oligonucleotides That Modify the Aberrant Splicing Patierns of Thalassemic Pre-mRNAs. Nucleosides & Nucleotides, 1997, 16, 1173-1182.	0.5	11
149	Patent strategies in the antisense oligonucleotide based therapeutic approach. Expert Opinion on Therapeutic Patents, 1997, 7, 1175-1182.	2.4	4
150	The Multiple Inhibitory Mechanisms of GEM 91Â®, agagAntisense Phosphorothioate Oligonucleotide, for Human Immunodeficiency Virus Type 1. AIDS Research and Human Retroviruses, 1997, 13, 545-554.	0.5	42
151	Effects of synthetic oligonucleotides on human complement and coagulationâ^—. Biochemical Pharmacology, 1997, 53, 1123-1132.	2.0	43
152	In vivo studies with antisense oligonucleotides. Trends in Pharmacological Sciences, 1997, 18, 12-18.	4.0	180
153	N-pent-4-enoyl (PNT) group as a universal nucleobase protector: Applications in the rapid and facile synthesis of oligonucleotides, analogs, and conjugates. Tetrahedron, 1997, 53, 2731-2750.	1.0	16
154	Perspectives in antisense therapeutics. , 1997, 76, 151-160.		61
155	Bioreversible oligonucleotide conjugates by site-specific derivatization. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 871-876.	1.0	18
156	The use of gaseous ammonia for the deprotection and cleavage steps during the solid-phase synthesis of oligonucleotides, and analogs. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1443-1448.	1.0	13
157	Antisense oligonucleotides as antiviral agents. Advances in Antiviral Drug Design, 1996, , 1-39.	0.7	7
158	Hoogsteen DNA Duplexes of 3â€˜â^’3â€˜- and 5â€˜â^’5â€˜-Linked Oligonucleotides and Triplex Formation with RNA and DNA Pyrimidine Single Strands:Â Experimental and Molecular Modeling Studies. Biochemistry, 1996, 35, 15332-15339.	1.2	34
159	Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochemical Pharmacology, 1996, 51, 173-182.	2.0	167
160	Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs. Biochemical Pharmacology, 1996, 52, 1537-1544.	2.0	23
161	Antisense oligonucleotides: towards clinical trials. Trends in Biotechnology, 1996, 14, 376-387.	4.9	262
162	3â€²-3â€²-linked oligonucleotides: Synthesis and stability studies. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 827-832.	1.0	14

#	Article	IF	Citations
163	Synthesis, biophysical properties, and stability studies of mixed backbone oligonucleotides containing segments of methylphosphotriester internucleotidic linkages. Tetrahedron, 1996, 52, 14419-14436.	1.0	12
164	Mixed backbone oligonucleotides containing internucleotidic primary phosphoramidate linkages. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2663-2668.	1.0	11
165	Pharmacokinetics of an antiâ€"human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects*. Clinical Pharmacology and Therapeutics, 1995, 58, 44-53.	2.3	122
166	Enzymatic Synthesis of Stereoregular (All Rp) Oligonucleotide Phosphorothioate and Its Properties. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 985-990.	0.4	29
167	Synthesis and Properties of 2'-O-Methylribonucleotide Methylphosphonate Containing Chimeric Oligonucleotides. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 1031-1035.	0.4	7
168	Design, biochemical, biophysical and biological properties of cooperative antisense oligonucleotides. Nucleic Acids Research, 1995, 23, 3578-3584.	6.5	22
169	Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM) Tj ETQq1 1 0.784314 rgBT /Ove Pharmacology, 1995, 49, 929-939.	2.0	121
170	In vivo stability, disposition and metabolism of a â€œhybridâ€•oligonucleotide phosphorothioate in rats. Biochemical Pharmacology, 1995, 50, 545-556.	2.0	97
171	Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochemical Pharmacology, 1995, 50, 571-576.	2.0	133
172	Large-Scale Synthesis, Purification, and Analysis of Oligodeoxynucleotide Phosphorothioates. Antisense Research and Development, 1994, 4, 185-199.	3.3	61
173	Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides in the Monkey. Antisense Research and Development, 1994, 4, 201-206.	3.3	239
174	Synthesis of di-, tri-, and tetrameric building blocks with novel carbamate internucleoside linkages and their incorporation into oligonucleotides. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 1065-1070.	1.0	14
175	Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2â€²-o- methyloligoribonucleotides. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 2929-2934.	1.0	59
176	Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity. Nucleic Acids Research, 1993, 21, 2729-2735.	6.5	103
177	Pharmacokinetics, Biodistribution, and Stability of Capped Oligodeoxynucleotide Phosphorothioates in Mice. Antisense Research and Development, 1993, 3, 277-284.	3.3	73
178	Antisense oligonucleotides as antiviral agents. Trends in Biotechnology, 1992, 10, 152-158.	4.9	135
179	Ion-exchange high-performance liquid chromatography analysis of oligodeoxyribonucleotide phosphorothioates. Analytical Biochemistry, 1992, 200, 342-346.	1.1	49
180	Oligodeoxynucleoside methylphosphonates: synthesis and enzymic degradation. Tetrahedron Letters, 1987, 28, 3539-3542.	0.7	109

#	Article	IF	Citations
181	Efficient methods for attaching non-radioactive labels to the 5â€² ends of synthetic oligodeoxyribonucleotides. Nucleic Acids Research, 1986, 14, 6227-6245.	6.5	225